ESMO GU Cancers Spotlight

Invikafusp alfa shows promising antitumor activity in TMB-H and MSI-H tumors resistant to immunotherapy, offering new hope for patients.

Fruquintinib plus sintilimab significantly enhances progression-free survival in advanced renal cell carcinoma, offering a promising second-line treatment option.

Patients with metastatic hormone-sensitive prostate cancer report stable health-related quality of life while receiving niraparib and abiraterone acetate in the AMPLITUDE trial.

New findings reveal that adding durvalumab to chemotherapy enhances survival in muscle-invasive bladder cancer without harming quality of life.

A phase 1/2 trial shows saruparib combined with ARPI offers high response rates and manageable safety in metastatic prostate cancer patients.

New research suggests using mpMRI for bladder cancer staging improves survival rates, potentially changing standard diagnostic practices.

A new treatment regimen for metastatic prostate cancer shows significant reductions in severe adverse events, offering a promising alternative for patients.

Atezolizumab shows no significant benefit over BCG alone in treating high-risk non-muscle invasive bladder cancer, according to the ALBAN trial results.

Discover the most anticipated abstracts on renal cell carcinoma and bladder cancer at the 2025 ESMO Congress in Berlin.

Vote on the latest breakthroughs in renal and bladder cancer at ESMO 2025, featuring pivotal late-breaking abstracts.